OTC : GNMSF

Genmab A/S

$282 USD

-$3.85 (-1.35%)

Volume
1
Average Volume
1.99K
Market Capitalization
$17.31B
P/E Ratio
21.51
Dividend Yield
0.00%
Price Target
Year High
$352.00
Year Low
$208.80
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.18
Company Overview

OTC

Jan van de Winkel

Biotechnology

Healthcare

GNMSF

3088

DK

USD

https://www.genmab.com

45 70 20 27 28

N/A

0001434265

Liquidity Metrics

0.94

2.18

2.17

1.29

0.00

Sales & Valuation

$3.85B

1.87

3.09

20.10

14.24

Profitability

$15.9

$996.93M

8.72%

10.99%

14.55%

6.64%

P/E Metrics

21.51

-0.25

-0.25

Analyst Price Target & Rating

Neutral

3/5

11 Analysts

%

Poll Results

About Genmab A/S (OTC:GNMSF) Stock

Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. The company markets several key products, including DARZALEX (daratumumab) for multiple myeloma, teprotumumab for thyroid eye disease, ofatumumab to address chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric, esophageal, and non-small cell lung cancers. Their extensive pipeline includes daratumumab, also being explored for non-MM blood cancers and AL amyloidosis, along with GEN1047, tisotumab vedotin for cervical, ovarian, and other solid cancers, and specialized DuoBody and HexaBody platforms targeting various solid tumors and hematological malign ... ancies, such as Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and CLL. Genmab further maintains approximately 20 active pre-clinical programs and a diverse array of compounds in Phase 2 development, investigating treatments for conditions like vaso-occlusive crises (Teclistamab), Hodgkin lymphoma and solid tumors (Camidanlumab tesirine), multiple myeloma (JNJ-64007957 and JNJ-64407564), celiac disease (PRV-015), hemophilia A (Mim8), and multiple system atrophy (Lu AF82422). The company engages in significant strategic collaborations, notably with Seagen Inc. for the co-development of tisotumab vedotin, CureVac AG for mRNA-based antibody products, and AbbVie for Epcoritamab, alongside other partnerships with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript

2026-05-14 08:43:03

Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Genmab A/S (GNMSF) stock price?

Genmab A/S(OTC:GNMSF) stock price is $282 in the last trading session. During the trading session, GNMSF stock reached the peak price of $352 while $208.8 was the lowest point it dropped to. The percentage change in GNMSF stock occurred in the recent session was --1.35% while the dollar amount for the price change in GNMSF stock was -$3.85.

GNMSF's industry and sector of operation?

The OTC listed GNMSF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of GNMSF?

Christopher Cozic | Executive Vice President & Chief People Officer
Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer
Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director
Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director
Jan van de Winkel | Co-Founder, President & Chief Executive Officer

How many employees does GNMSF have?

Number of GNMSF employees currently stands at 3088. GNMSF operates from Carl Jacobsens Vej 30, Copenhagen, CD 1560, DK.

Link for GNMSF official website?

Official Website of GNMSF is: https://www.genmab.com

How do I contact GNMSF?

GNMSF could be contacted at phone #45 70 20 27 28 and can also be accessed through its website. GNMSF operates from Carl Jacobsens Vej 30, Copenhagen, CD 1560, DK.

How many shares of GNMSF are traded daily?

The average number of GNMSF shares traded daily for last 3 months was 1.99K.

What is the market cap of GNMSF currently?

The market value of GNMSF currently stands at $17.31B with its latest stock price at $282